Brokerages expect Bausch Health Companies Inc. (NYSE:BHC – Get Rating) to post earnings per share of $0.97 for the current fiscal quarter, according to Zacks Investment Research. Four analysts have provided estimates for Bausch Health Companies’ earnings, with estimates ranging from $0.76 to $1.11. Bausch Health Companies reported earnings of $0.98 per share during the same quarter last year, which indicates a negative year over year growth rate of 1%. The company is scheduled to issue its next earnings results on Monday, January 1st.
On average, analysts expect that Bausch Health Companies will report full year earnings of $4.15 per share for the current financial year, with EPS estimates ranging from $3.67 to $4.87. For the next year, analysts forecast that the business will post earnings of $4.69 per share, with EPS estimates ranging from $4.09 to $5.11. Zacks Investment Research’s earnings per share averages are a mean average based on a survey of research firms that that provide coverage for Bausch Health Companies.
Bausch Health Companies (NYSE:BHC – Get Rating) last issued its quarterly earnings results on Wednesday, February 23rd. The company reported $1.27 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.08 by $0.19. The business had revenue of $2.20 billion for the quarter, compared to analysts’ expectations of $2.21 billion. Bausch Health Companies had a negative net margin of 4.89% and a negative return on equity of 649.29%. The business’s quarterly revenue was down .8% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.33 earnings per share.
In other Bausch Health Companies news, insider Robert Spurr sold 4,846 shares of the company’s stock in a transaction that occurred on Tuesday, March 15th. The stock was sold at an average price of $22.20, for a total value of $107,581.20. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Joseph F. Gordon sold 3,889 shares of the company’s stock in a transaction on Tuesday, March 8th. The stock was sold at an average price of $21.76, for a total value of $84,624.64. The disclosure for this sale can be found here. Insiders sold a total of 16,668 shares of company stock valued at $378,570 in the last 90 days. 13.75% of the stock is owned by company insiders.
Institutional investors and hedge funds have recently modified their holdings of the stock. Vanguard Group Inc. grew its stake in shares of Bausch Health Companies by 3.4% in the first quarter. Vanguard Group Inc. now owns 10,225,558 shares of the company’s stock worth $233,653,000 after purchasing an additional 335,045 shares in the last quarter. Laurion Capital Management LP lifted its holdings in shares of Bausch Health Companies by 28.6% in the fourth quarter. Laurion Capital Management LP now owns 9,689,643 shares of the company’s stock valued at $267,532,000 after buying an additional 2,152,863 shares during the period. Guardian Capital LP lifted its holdings in shares of Bausch Health Companies by 1.3% in the first quarter. Guardian Capital LP now owns 3,884,769 shares of the company’s stock valued at $88,827,000 after buying an additional 51,439 shares during the period. Clear Street LLC acquired a new stake in shares of Bausch Health Companies in the fourth quarter valued at $102,158,000. Finally, Norges Bank acquired a new stake in shares of Bausch Health Companies in the fourth quarter valued at $94,276,000. Hedge funds and other institutional investors own 73.38% of the company’s stock.
Shares of Bausch Health Companies stock opened at $9.93 on Friday. The firm has a market capitalization of $3.58 billion, a P/E ratio of -8.71, a P/E/G ratio of 0.22 and a beta of 1.62. Bausch Health Companies has a 52 week low of $7.80 and a 52 week high of $32.54. The firm’s 50 day moving average is $19.66 and its two-hundred day moving average is $23.39.
About Bausch Health Companies (Get Rating)
Bausch Health Companies Inc, together with its subsidiaries, develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through five segments: Bausch + Lomb, Salix, International Rx, Ortho Dermatologics, and Diversified Products.
- Get a free copy of the StockNews.com research report on Bausch Health Companies (BHC)
- MarketBeat: Week in Review 5/16 – 5/20
- 3 Retailers That Defied First Quarter Headwinds
- Will John Deere’s Earnings Help to Calm the Markets?
- Rapid7: Could Be Profitable in FY 2022 Despite Bear Market
- Lowe’s Companies Has Not Bottomed
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Bausch Health Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bausch Health Companies and related companies with MarketBeat.com's FREE daily email newsletter.